For most of a decade, Lance Armstrong was the greatest comeback story in sport: a Texan who survived metastatic testicular cancer in 1996 and then won the Tour de France seven straight times, from 1999 to 2005. On August 24, 2012, the United States Anti-Doping Agency stripped all of it. He declined to contest the charges in arbitration, and USADA imposed a lifetime ban and disqualified every result he had recorded since August 1, 1998. On October 22, 2012, cycling’s governing body, the UCI, accepted the sanction and formally erased the seven titles. The Tour chose not to award them to anyone else. The record book for 1999 through 2005 now reads blank, which is its own kind of verdict.
The case against him was not a failed drug test. It was, in USADA’s published account, “the most sophisticated, professionalized and successful doping program that sport has ever seen” — a team-wide system on the US Postal Service squad built around EPO, blood transfusions, testosterone, cortisone, and human growth hormone, with saline infusions and careful timing used to stay ahead of the testers. USADA laid it out in October 2012 in a roughly 200-page Reasoned Decision backed by more than a thousand pages of evidence and the sworn testimony of 26 witnesses, including 15 riders and 11 of Armstrong’s own former teammates.
For years Armstrong’s defense had been four words long — I never failed a test — and in the narrow, technical sense it was almost true, which was precisely the problem the evidence exposed. He had not been caught by a vial of urine. He had been caught by the people who had doped alongside him. The man who had sued his accusers for defamation, and won settlements doing it, confessed the whole thing to Oprah Winfrey on television in January 2013.
The fall was not only reputational. Sponsors left in a single day; he stepped down from the cancer foundation he had built; and in 2018 he paid the US government $5 million to settle a whistleblower fraud suit brought by the teammate who had started the unravelling. What follows is how the most tested athlete in cycling ran the sport’s most elaborate doping program in plain sight, and how it finally came apart from the inside.
On September 24, 1988, Ben Johnson of Canada ran the men’s 100 metres final at the Seoul Olympics in 9.79 seconds, beat his great rival Carl Lewis, lowered his own world record, and stood at the top of the medal stand as, by acclamation, the fastest man who had ever lived. Three days later it was all gone. His post-race urine sample contained stanozolol, an anabolic steroid; the International Olympic Committee disqualified him, stripped the gold and the world record, and handed the title to Lewis. The verdict on the most famous nine seconds in track history was: stripped.
The mechanism was not subtle. Johnson had been on steroids for years — his own coach would later testify, under oath, that the program dated to 1981 — and the only genuine miscalculation was one of timing. Stanozolol is a synthetic steroid the body clears slowly, and Seoul’s anti-doping laboratory was looking for exactly that class of compound. A man who had spent the better part of a decade beating the system was undone by the elementary arithmetic of how long a drug stays in the body.
The fall was bottomless because the height had been absurd. Johnson was not merely an Olympic champion; he was a national hero in Canada and the headline act of a sport that had sold the Lewis-Johnson rivalry as a clean morality play. When the test came back, the Canadian government did not issue a statement and move on — it convened a judicial inquiry, the Dubin Commission, which sat for 91 days and turned the private machinery of elite-sprint doping inside out for a watching country.
Johnson got one chance to come back, and burned it. In January 1993, racing again after his suspension, he tested positive a second time, for excess testosterone. Under the governing body’s rules a second offence meant one outcome only, and he was banned from athletics for life. The man who had been the fastest alive for three days in 1988 spent the rest of his career as the sport’s permanent cautionary tale: the cheat who got caught, and then, given a second life, got caught again.
Marion Jones arrived at the Sydney 2000 Olympics promising to win five track-and-field medals and left having won exactly that — three gold (100m, 200m, 4x400m relay) and two bronze (long jump, 4x100m relay) — the most decorated American woman of the Games and, for the better part of a decade, one of the most celebrated athletes in the world. On December 12, 2007, the International Olympic Committee disqualified her from all five events and stripped every medal. The verdict on the haul was: stripped.
The substance at the centre of it was “the clear,” a designer steroid known as THG, supplied through the Bay Area Laboratory Co-operative — BALCO — that for years sat undetectable because no test had been designed to look for it. Jones’s coach, Trevor Graham, gave it to her; she would later say he told her it was flaxseed oil, a claim that is either the truth or the most convenient version of it, and which in the end mattered to no authority that ruled on her case.
What destroyed Marion Jones was not, in the strict sense, the doping. It was the lying about it. For years she denied any use of performance-enhancing drugs, sued an accuser, and built a public defence on indignant denial. When federal investigators questioned her in connection with the BALCO inquiry — and a separate check-fraud scheme — she lied to them, and lying to federal agents is itself a crime. On October 5, 2007, she pleaded guilty in a New York federal court to two counts of making false statements. On January 11, 2008, she was sentenced to six months in prison. The medals were a sporting matter; the cell was a criminal one.
The case is the clearest illustration in the doping canon of a particular lesson: that the cover-up is reliably more dangerous than the conduct it conceals. The doping cost Jones her medals, records, sponsors, and reputation — serious, but survivable. The denial, sustained to federal agents, cost her freedom. The record now reads that the woman who won five medals in Sydney won none of them, and went to prison for insisting otherwise.
Maria Sharapova, the five-time Grand Slam champion and for eleven straight years the world’s highest-earning female athlete, was banned for doping in 2016 — not for a steroid or a transfusion, but for a Latvian heart drug she had been taking openly for a decade, which the World Anti-Doping Agency had added to its prohibited list on the first day of that year. She tested positive at the Australian Open in January; the International Tennis Federation banned her two years in June; and on appeal the Court of Arbitration for Sport cut the sanction to fifteen months in October 2016, holding that she had not cheated on purpose but had still failed to do the one thing required of her — check whether her medication was still legal.
The substance was meldonium, sold under the brand name Mildronate, manufactured in Latvia and prescribed across the former Soviet bloc. Sharapova said a family doctor had put her on it in 2006 for a cluster of complaints — frequent illness, irregular EKG readings, a family history of diabetes. WADA banned it effective January 1, 2016, on evidence that athletes were using it to aid endurance and recovery. Sharapova kept taking it, and on January 26, 2016, a sample at the Australian Open came back positive. She had, in the most literal sense, been doping with a drug she had declared to no one because she had stopped reading the list that now contained it.
What makes the case unusual is how little of it turned on chemistry and how much on paperwork. Nobody disputed what was in her system or why. The fight was entirely about fault — how careless an athlete has to be, and how clearly a federation has to warn, before a positive for a newly banned drug becomes two years rather than fifteen months. The CAS panel found fault on both sides, hers for not checking and the testers’ for burying the change in a wall of email, and split the difference.
It cost her the back half of a season, a chunk of her ranking, and the immediate suspension of contracts with Nike, Porsche, and TAG Heuer. It did not cost her a Grand Slam title; the only result disqualified was her quarter-final at the 2016 Australian Open. The verdict on record is a ban, and a relatively short one, for the rarest kind of doping case: the athlete caught by a change of rules rather than a change of behaviour.
Alberto Contador, the Spanish climber who had already won three Tours de France and was the dominant stage racer of his generation, was stripped of his 2010 Tour de France title and his 2011 Giro d’Italia victory after the Court of Arbitration for Sport ruled, on February 6, 2012, that he had committed a doping offence. The substance was clenbuterol, found in a urine sample on the second rest day of the 2010 Tour. The amount was vanishingly small — fifty picograms per millilitre, a level so low that the case became less about whether the drug was there than about how it had got there. CAS handed him a two-year ban backdated to January 25, 2011, and erased everything he had won in between.
The defence was a steak. Contador’s team argued that a friend had brought beef across the border from Spain, and that the meat had been contaminated with clenbuterol — a drug given illegally to cattle in some countries to build lean muscle. It was not an absurd story; meat contamination is real enough that WADA has formally warned athletes about it in China and Mexico. But under strict liability, an athlete is responsible for what is in his body regardless of how it arrived, and the only way out is to prove the innocent route on the balance of probabilities. Contador could not.
The institutional path was as much the story as the chemistry. After the positive was announced in September 2010, the matter went to the Spanish cycling federation, the RFEC, which first proposed a one-year ban and then, in early 2011, cleared Contador entirely. The Union Cycliste Internationale and the World Anti-Doping Agency each appealed that acquittal to CAS — the court that sits above national federations precisely so that a home body cannot have the final word on its own star. CAS overturned the clearance, the rare and telling feature of the case: an athlete acquitted at home, convicted on appeal.
CAS, notably, did not endorse the steak. Investigators found no clenbuterol in the traced beef, and the panel judged meat contamination very unlikely; it also rejected the prosecution’s theory of a blood transfusion as unproven. Its actual finding was a third option: that the most probable source was a contaminated food supplement. The verdict on record, then, is a two-year ban and two vacated Grand Tours, resting not on proof of how the drug entered Contador’s body but on his failure to prove it had entered innocently.
Kamila Valieva was fifteen years old when she skated at the 2022 Beijing Winter Olympics, and fifteen when a sample she had given six weeks earlier was revealed, mid-Games, to contain a banned heart medication. On January 29, 2024, the Court of Arbitration for Sport found that she had committed an anti-doping rule violation, imposed a four-year ban backdated to December 25, 2021, and disqualified all of her results from that date — including the Olympic team event in which she had skated for the Russian Olympic Committee. As a consequence, the ROC’s team gold was lost: the International Skating Union re-ranked the event, elevating the United States to gold and Japan to silver.
The substance was trimetazidine, an anti-anginal drug that improves cardiac efficiency and is banned in sport. The sample was collected on December 25, 2021, at the Russian national championships by RUSADA. The result should have been processed in days. Instead the WADA-accredited Stockholm laboratory did not report the positive until February 8, 2022 — after Valieva had already helped the ROC win the team event in Beijing. The timing detonated the Games’ most painful controversy, and it was a failure of the adult laboratory and reporting system, not of the child who had given the sample.
Because she was fifteen, Valieva was a “protected person” under the World Anti-Doping Code — a category created to shield minors, who cannot reasonably be held to an adult’s standard of personal responsibility, and to direct scrutiny toward the coaches, doctors, and officials around them. A CAS ad hoc panel cited that status during the Games in allowing her to keep competing; the final ruling two years later still imposed the standard four-year sanction, holding that her protected status did not eliminate the consequence. But the question her case forced was never really about a teenager’s culpability. It was about the system of adults that put a banned drug into the body of a child and then took six weeks to say so — and this dossier aims its scrutiny where it belongs, at the entourage and the institutions. The skater at the centre was a minor, the person the Code exists to protect.
Sun Yang, the most decorated swimmer China has produced and a three-time Olympic champion, was banned in 2021 for four years and three months — not for a drug found in his body, but for what happened to a vial of his blood. On the night of 4 September 2018, anti-doping officials arrived at his home to collect samples. By the time they left, a container holding his blood had been smashed with a hammer, and the case the testers had come to fill went unfilled. The verdict on record is a refusal-and-tampering sanction handed down by the Court of Arbitration for Sport, not a positive test, and the distinction is the whole story.
The mechanism was almost defiantly simple. Sun and his entourage disputed the credentials of the doping-control personnel; an argument escalated; and rather than let the sample leave with testers he deemed unauthorized, a member of his camp used a hammer to break open the container so the blood could not be carried away. Under the World Anti-Doping Code, destroying or tampering with a sample is itself an anti-doping rule violation, treated as seriously as a positive result. An athlete does not get to adjudicate the legitimacy of his own drug test in real time and then dismantle the evidence when he loses the argument.
The case then took a detour that few doping disputes ever take. CAS first banned Sun for eight years in February 2020 — the maximum available. He appealed to the Swiss Federal Tribunal, which in December 2020 set that ruling aside, not on the facts but because the chairman of the arbitration panel had posted offensive social-media comments that gave objectively justified doubts about his impartiality. The case went back for a fresh hearing before a new panel, which in June 2021 reached the same conclusion on the merits and reduced the ban to four years and three months, treating it as Sun’s second violation.
What it cost him was the prime of a career. The ban, calculated to run from the date of the original award, kept Sun out of the Tokyo Olympics, where he would have defended his 200-metre freestyle title. He did not return to eligibility until May 2024, by then in his thirties. He lost no medals to disqualification, because the offence was not a doping positive that invalidated a result. He lost something harder to award to a runner-up: the years.
Rashid Ramzi, the Moroccan-born middle-distance runner who competed for Bahrain, won the 1500 metres at the 2008 Beijing Olympics and, on November 18, 2009 — some fifteen months later — was stripped of the gold by the International Olympic Committee for doping with CERA, a third-generation form of EPO. He had passed his doping controls at the Games. The samples were not flawed; the test had simply not yet been good enough to read them, and when it improved, the IOC went back and read them again. Kenya’s Asbel Kiprop was promoted to gold, New Zealand’s Nicholas Willis to silver, and France’s Mehdi Baala to bronze. Ramzi was the only champion of the Beijing Games caught in the re-analysis.
The substance was the case’s signature. CERA — continuous erythropoietin receptor activator, sold by Roche as Mircera under the generic name methoxy polyethylene glycol-epoetin beta — is an engineered descendant of recombinant EPO designed to last far longer in the body, with the longest half-life of any approved erythropoiesis-stimulating agent. That endurance is the point for a kidney patient, who can be dosed once or twice a month instead of several times a week. It is also, for an athlete trying to evade detection, a serious miscalculation: a molecule built to linger is a molecule that lingers in a stored sample, waiting to be found. CERA had been approved in Europe in August 2007 and by the US FDA in January 2008, and within months it was turning up at the 2008 Tour de France. By Beijing, the laboratories were closing the gap.
The mechanism that undid Ramzi was not a tip-off or a confession but the IOC’s policy of freezing Olympic samples and re-testing them when the science advances. The Beijing samples were collected in August 2008 and cleared at the time. In 2009, once a fully validated CERA assay existed, the IOC thawed a batch and ran it again. Five athletes failed the second look; Ramzi’s was the only gold among them. His B-sample was confirmed positive in July 2009, and the IOC ratified the disqualification that November.
What followed was comparatively quiet. Ramzi, who had been the first Bahraini to win an Olympic athletics title and one of the few men ever to take the 800m–1500m double at a World Championships, lost the medal and served a two-year ban. There was no career rehabilitation to forgive, because there was barely a career left. The case endures less for its drama than for what it proved about time: that the finish line is not the end of the contest, and that a clean result in 2008 was only ever provisional.
Justin Gatlin, the American sprinter who won the Olympic 100m in Athens in 2004, was banned from athletics in 2006 after testing positive for testosterone, a sanction that annulled the 9.77-second world record he had set weeks earlier and, because it counted as his second doping offence, very nearly ended his career for good. The United States Anti-Doping Agency initially announced an eight-year ban — a near-lifetime penalty for a sprinter then 24 — which an arbitration panel reduced to four years in December 2007. Gatlin returned to competition in August 2010, and then did the thing the sport could not metabolize: he won. Olympic bronze in 2012, Olympic silver in 2016, and a world title in 2017 in which he beat Usain Bolt in Bolt’s final individual race. The medals were legitimate. The booing that greeted them was a verdict the rule book could not impose.
The 2006 case was, on its face, simple. An in-competition test at the Kansas Relays on April 22, 2006 returned positive for testosterone or its precursors. The B-sample confirmed it that July. The complication was history. Five years earlier, as a freshman at the University of Tennessee, Gatlin had tested positive for an amphetamine at the 2001 US junior championships — a finding traced to Adderall he had taken since childhood for attention-deficit disorder. An arbitration panel at the time called him “certainly not a doper” and the violation “at most, a technical or a paperwork” matter, and the IAAF granted early reinstatement on the strength of the medical explanation. It was, by any reasonable reading, the least sinister positive test imaginable. Under the rules, it was still a first offence.
That technicality governed everything that followed. A first amphetamine positive plus a testosterone positive is, in anti-doping arithmetic, a repeat offender, and the testosterone case therefore carried the weight of a second strike regardless of how innocuous the first had been. Gatlin’s camp blamed a massage therapist for rubbing a testosterone cream onto him without his knowledge — an explanation never substantiated — but the substance, the test, and the prior record were not in dispute. The eight-year ban reflected the recidivism; the reduction to four reflected his cooperation and the genuine ambiguity of the 2001 case.
What the verdict could not settle was the matter of forgiveness. Gatlin served his time, came back, and ran faster in his thirties than most men do in their twenties, which left the sport in an awkward position: he had paid the penalty the system prescribed and was therefore entitled to compete, yet he was treated as the ban had never lifted. The crowds booed an athlete who was, by the rules’ own logic, rehabilitated. His career became the test case for a question the sport has never resolved — whether a served sentence is a clean slate, or merely permission to be hated in public.